Background: The aim of this study was to compare two measures of depression in patients with schizophrenia and schizophrenia spectrum disorder, including patients with delusional and schizoaffective disorder, to conclude implications for their application. Sampling and Methods: A total of 278 patients were assessed using the Calgary Depression Scale for Schizophrenia (CDSS) and the Hamilton Depression Rating Scale (HAMD-17). The Positive and Negative Syndrome Scale (PANSS) was also applied. At admission and discharge, a principal component analysis was performed with each depression scale. The two depression rating scales were furthermore compared using correlation and regression analyses. Results: Three factors were revealed for the CDSS and HAMD-17 factor component analysis. A very similar item loading was found for the CDSS at admission and discharge, whereas results of the loadings of the HAMD-17 items were less stable. The first two factors of the CDSS revealed correlations with positive, negative and general psychopathology. In contrast, multiple significant correlations were found for the HAMD-17 factors and the PANSS subscores. Multiple regression analyses demonstrated that the HAMD-17 accounted more for the positive and negative symptom domains than the CDSS. Conclusions: The present results suggest that compared to the HAMD-17, the CDSS is a more specific instrument to measure depressive symptoms in schizophrenia and schizophrenia spectrum disorder, especially in acutely ill patients.

1.
Sands JR, Harrow M: Depression during the longitudinal course of schizophrenia. Schizophr Bull 1999;25:157–171.
2.
Zisook S, McAdams LA, Kuck J, Harris MJ, Bailey A, Patterson TL, Judd LL, Jeste DV: Depressive symptoms in schizophrenia. Am J Psychiatry 1999;156:1736–1743.
3.
Tollefson GD, Andersen SW: Should we consider mood disturbance in schizophrenia as an important determinant of quality of life? J Clin Psychiatry 1999;60(suppl 5):23–29, discussion 30.
4.
Resnick SG, Rosenheck RA, Lehman AF: An exploratory analysis of correlates of recovery. Psychiatr Serv 2004;55:540–547.
5.
Moller H-J: Drug treatment of depressive symptoms in schizophrenia. Clin Schizophr Relat Psychoses 2008;1:328–340.
6.
Conley RR: The burden of depressive symptoms in people with schizophrenia. Psychiatr Clin North Am 2009;32:853–861.
7.
Craig TJ, Richardson MA, Pass R, Bregman Z: Measurement of mood and affect in schizophrenic inpatients. Am J Psychiatry 1985;142:1272–1277.
8.
Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56–62.
9.
Goldman RS, Tandon R, Liberzon I, Greden JF: Measurement of depression and negative symptoms in schizophrenia. Psychopathology 1992;25:49–56.
10.
Addington D, Addington J, Schissel B: A depression rating scale for schizophrenics. Schizophr Res 1990;3:247–251.
11.
Sarro S, Duenas RM, Ramirez N, Arranz B, Martinez R, Sanchez JM, Gonzalez JM, Salo L, Miralles L, San L: Cross-cultural adaptation and validation of the Spanish version of the Calgary Depression Scale for Schizophrenia. Schizophr Res 2004;68:349–356.
12.
Reine G, Bernard D, Auquier P, Le FB, Lancon C: Psychometric properties of French version of the Calgary depression scale for schizophrenics (CDSS) (in French). Encephale 2000;26:52–61.
13.
Bernard D, Lancon C, Auquier P, Reine G, Addington D: Calgary Depression Scale for Schizophrenia: a study of the validity of a French-language version in a population of schizophrenic patients. Acta Psychiatr Scand 1998;97:36–41.
14.
Addington D, Addington J, Atkinson M: A psychometric comparison of the Calgary Depression Scale for Schizophrenia and the Hamilton Depression Rating Scale. Schizophr Res 1996;19:205–212.
15.
Müller MJ, Müller KM, Fellgiebel A: Detection of depression in acute schizophrenia: sensitivity and specificity of 2 standard observer rating scales. Can J Psychiatry 2006;51:387–392.
16.
Collins AA, Remington G, Coulter K, Birkett K: Depression in schizophrenia: a comparison of three measures. Schizophr Res 1996;20:205–209.
17.
Wolwer W, Buchkremer G, Hafner H, Klosterkotter J, Maier W, Moller HJ, Gaebel W: German research network on schizophrenia – bridging the gap between research and care. Eur Arch Psychiatry Clin Neurosci 2003;253:321–329.
18.
Jager M, Riedel M, Messer T, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Huff W, Heuser I, Kuhn KU, Lemke MR, Ruther E, Buchkremer G, Gastpar M, Bottlender R, Strauss A, Möller HJ: Psychopathological characteristics and treatment response of first episode compared with multiple episode schizophrenic disorders. Eur Arch Psychiatry Clin Neurosci 2007;257:47–53.
19.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, American Psychiatric Association, 1994.
20.
Cording C: Conceptual aspects in development and implementation of basic psychiatric documentation (in German). Psychiatr Prax 1998;25:175–178.
21.
Addington D, Addington J, Maticka-Tyndale E: Assessing depression in schizophrenia: the Calgary Depression Scale. Br J Psychiatry Suppl 1993;(22):39–44.
22.
Kay SR, Opler LA, Lindenmayer JP: Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Res 1988;23:99–110.
23.
Jager M, Riedel M, Schmauss M, Pfeiffer H, Laux G, Naber D, Gaebel W, Huff W, Schmidt LG, Heuser I, Buchkremer G, Kuhn KU, Ruther E, Hoff P, Gastpar M, Bottlender R, Strauss A, Möller HJ: Depression during an acute episode of schizophrenia or schizophreniform disorder and its impact on treatment response. Psychiatry Res 2008;158:297–305.
24.
Humphreys LG, Montanelli RG: An investigation of the parallel analysis criterion for determining the number of common factors. Multivariate Behav Res 1975;10:193–206.
25.
R Development Core Team: R: a language and environment for statistical computing. Vienna, Foundation for Statistical Computing, 2008. http://www.R-project.org.
26.
Maggini C, Raballo A: Exploring depression in schizophrenia. Eur Psychiatry 2006;21:227–232.
27.
Muller MJ, Brening H, Gensch C, Klinga J, Kienzle B, Muller KM: The Calgary Depression Rating Scale for schizophrenia in a healthy control group: psychometric properties and reference values. J Affect Disord 2005;88:69–74.
28.
Kontaxakis VP, Havaki-Kontaxaki BJ, Stamouli SS, Margariti MM, Collias CT, Christodoulou GN: Comparison of four scales measuring depression in schizophrenic inpatients. Eur Psychiatry 2000;15:274–277.
29.
Lancon C, Auquier P, Reine G, Bernard D, Toumi M: Study of the concurrent validity of the Calgary Depression Scale for Schizophrenics (CDSS). J Affect Disord 2000;58:107–115.
30.
Kim SW, Kim SJ, Yoon BH, Kim JM, Shin IS, Hwang MY, Yoon JS: Diagnostic validity of assessment scales for depression in patients with schizophrenia. Psychiatry Res 2006;144:57–63.
31.
Tapp A, Kilzieh N, Wood AE, Raskind M, Tandon R: Depression in patients with schizophrenia during an acute psychotic episode. Compr Psychiatry 2001;42:314–318.
32.
Shafer AB: Meta-analysis of the factor structures of four depression questionnaires: Beck, CES-D, Hamilton, and Zung. J Clin Psychol 2006;62:123–146.
33.
Hamilton M: Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6:278–296.
34.
Bagby RM, Ryder AG, Schuller DR, Marshall MB: The Hamilton Depression Rating Scale: has the gold standard become a lead weight? Am J Psychiatry 2004;161:2163–2177.
35.
Fleck MP, Poirier-Littre MF, Guelfi JD, Bourdel MC, Loo H: Factorial structure of the 17-item Hamilton Depression Rating Scale. Acta Psychiatr Scand 1995;92:168–172.
36.
Rocca P, Bellino S, Calvarese P, Marchiaro L, Patria L, Rasetti R, Bogetto F: Depressive and negative symptoms in schizophrenia: different effects on clinical features. Compr Psychiatry 2005;46:304–310.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.